Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer

PURPOSE: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAF(V600E) metastatic colorectal cancer (mCRC). However, there is a need to improve the efficacy of this molecular-targeted therapy and evaluate regimens suitable for untreated BRAF(V600E) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Stefania, Woods, Melanie, Lee, Hey Min, De Falco, Vincenzo, Martini, Giulia, Della Corte, Carminia Maria, Martinelli, Erika, Famiglietti, Vincenzo, Ciardiello, Davide, Anderson, Amanda, Fowlkes, Natalie Wall, Villareal, Oscar Eduardo, Sorokin, Alexey, Kanikarla, Preeti, Coker, Olu, Morris, Van, Altucci, Lucia, Tabernero, Josep, Troiani, Teresa, Ciardiello, Fortunato, Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261917/
https://www.ncbi.nlm.nih.gov/pubmed/37040395
http://dx.doi.org/10.1158/1078-0432.CCR-22-3894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261917/
https://www.ncbi.nlm.nih.gov/pubmed/37040395
http://dx.doi.org/10.1158/1078-0432.CCR-22-3894

Ejemplares similares